Provided by Tiger Trade Technology Pte. Ltd.

INNOVENT BIO

102.400
+1.2001.19%
Volume:15.25M
Turnover:1.56B
Market Cap:178.59B
PE:186.75
High:104.000
Open:101.800
Low:100.600
Close:101.200
52wk High:109.100
52wk Low:69.550
Shares:1.74B
HK Float Shares:1.74B
Volume Ratio:1.10
T/O Rate:0.87%
Dividend:- -
Dividend Rate:- -
EPS(LYR):0.548
ROE:5.01%
ROA:1.56%
PB:7.91
PE(LYR):186.75
PS:11.74

Loading ...

Domestic Innovative Drugs Initiate Paradigm Shift in First-Line NSCLC Treatment, Says Orient Securities

Stock News
·
Jun 08

Movement Alert|Innovent Biologics Falls 3.59% in Regular Trading, Pfizer Deal Regulatory Approval Uncertainty Continues to Weigh on Stock

Market Focus
·
Jun 08

BUZZ-Innovent climbs most in a week on new drug application for gastric cancer

Reuters
·
Jun 05

Movement Alert|Innovent Biologics Rises 3.01% in Regular Trading, Global First CLDN18.2 ADC Drug Application Accepted for Gastric Cancer

Market Focus
·
Jun 05

Innovent Biologics Adds 10,000 Shares from Option Exercise; Issued Share Capital Reaches 1.74 Billion

Bulletin Express
·
Jun 04

Innovent Biologics' Application for Gastric Cancer Drug Accepted in China

MT Newswires Live
·
Jun 04

INNOVENT BIO Receives NMPA Priority Review for World’s First CLDN18.2 ADC Following Phase 3 Success

Bulletin Express
·
Jun 04

Innovent Biologics Announces NMPA Acceptance of New Drug Application for IBI343 in Advanced Gastric Cancer

Stock News
·
Jun 04

World's First Cldn18.2 ADC for Regulatory Review: Innovent Biologics Announces Ibi343 (Arcotatug Tavatecan) Met Primary Endpoint in International Phase 3 Study in Advanced Refractory Gastric Cancer and Nda Accepted by China Nmpa

THOMSON REUTERS
·
Jun 04

BRIEF-Innovent Biologics Says NMPA Accepts NDA For IBI343 (Arcotatug Tavatecan)

Reuters
·
Jun 04

Innovent says China regulator accepts IBI343 gastric cancer NDA for priority review

Reuters
·
Jun 04

Innovent Biologics - Nmpa Accepts Nda for Ibi343 (Arcotatug Tavatecan) for Advanced Gastric Cancer

THOMSON REUTERS
·
Jun 04

Southwest Securities Highlights Innovent Biologics' Strategic Collaboration with Pfizer to Accelerate Oncology Drug Development

Stock News
·
Jun 04

Jiao Yin International Retains 'Buy' Stance on Innovent Bio, Sets Target at HK$105

Stock News
·
Jun 03

Movement Alert|Innovent Biologics Falls 3.04% in Regular Trading, Pfizer Deal Regulatory Uncertainty and Biotech Sector Selloff Weigh on Shares

Market Focus
·
Jun 03

Stock Track | Innovent Biologics Plummets 5.01% Intraday on Pfizer Deal Regulatory Concerns and Biotech Sector Selloff

Stock Track
·
Jun 02

Movement Alert|Innovent Biologics Falls 3.15% in Regular Trading, Pfizer Deal Regulatory Uncertainty Compounds Biotech Sector Selloff

Market Focus
·
Jun 02

Movement Alert|Innovent Biologics Falls 3.12% in Regular Trading, Biotech Sector Pullback Compounds Pfizer Deal Regulatory Uncertainty

Market Focus
·
Jun 01

2026 Asco | Innovent Presents Long-Term Follow-up Results From the Poc Study of Ibi363 (Tak-928) (Pd-1/Il-2Α-Bias Bispecific Fusion Protein), Showing Robust Survival Benefits in Advanced Immunotherapy-Resistant Non-Small Cell Lung Cancer

THOMSON REUTERS
·
Jun 01

Asian Market's May 2026 Stocks Priced Below Estimated Value

Simply Wall St.
·
Jun 01